This clinical trial is for men and women age 18 and older with esophagogastric adenocarcinoma to check the safety, efficacy and tolerability of Telomelysin (OBP-301) in combination with Pembrolizumab.
In North America, gastric cancer is the third most common gastrointestinal malignancy and the third most lethal neoplasm overall. The standard primary therapy is surgical resection.
Despite advances in developing targeted therapies across solid tumor malignancies, progress in cancers of the upper gastrointestinal tract (esophagus and gastric cancers) has been limited. Despite recent advances, the average survival for metastatic disease is approximately 10 months, and more than 80% of patients diagnosed with an esophageal or gastric cancer will ultimately die of their disease. There is a need to find more effective treatment with better survival outcomes.
OBP-301 stimulates the immune system and may stop cancer cells from growing. The non-clinical and clinical observations suggest that OBP-301 and pembrolizumab combined therapy may produce superior anti-tumor activity compared to one drug alone.